EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy

María Errea Rodríguez, María Fernández, Juan Del Llano, Roberto Nuño-Solinís

Farmacia Hospitalaria · 2023

DOI: 10.1016/j.farma.2023.04.006 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Farmacia Hospitalaria, 2023. Verfasst von María Errea Rodríguez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Director of the Spanish Association for the Evaluation of Health Technologies, Pamplona, Navarra, Spain. Electronic address: maria.errea@aeets.es. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Stroke. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Post-stroke spasticity (PSS) is a common complication in stroke survivors, causing severe burden to patients living with it. The aim of this review was to conduct a cost-effectiveness analysis (CEA) of the treatment of post-stroke spasticity, in adults, with abobotulinumtoxinA compared to the best supportive care, based on results from a systematic literature review. Given that abobotulinumtoxinA (aboBoNT-A) is always accompanied by the best supportive care treatment, the CEA compared aboBoNT-A plus the best supportive care with the best supportive care alone. METHODS: A systematic literature review in EMBASE (including Medline and PubMed), Scopus, and other sources (Google Scholar) was conducted. Articles of all types, providing information on the costs and/or effectiveness measures for the current treatments of PSS in adults were included. The synthesis of information from the review provided the parameters for the design of a cost-effectiveness analysis of the mentioned treatment of interest. The societal perspective was compared to a perspective where only direct costs were observed. RESULTS: In total, 532 abstracts were screened. Full information was revised from 40 papers and 13 of these were selected as core papers for full data extraction. Data from the core publications formed the basis for the development of a cost-effectiveness model. In all the included papers physiotherapy was the best supportive care treatment (SoC). The cost-effectiveness analysis showed that even in the most conservative scenario, assuming the worst case scenario, the probability of a cost per quality-adjusted life-year (QALY) gained below €40,000, for aboBoNT-A together with physiotherapy is above 0.8, and with certainty below €50,000/QALY when either a direct costs, or a societal perspective was taken. On average, the probabilistic model obtains a negative mean incremental cost-effectiveness ratio of around -15,000 €/QALY. CONCLUSION: The cost-effectiveness analyses show that aboBoNT-A together with physiotherapy would be a cost-effective treatment compared with physiotherapy alone, independently of the perspective considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AStrokeAdultHumansCost-Effectiveness AnalysisCost-Benefit AnalysisPhysical Therapy ModalitiesQuality-Adjusted Life Years

Stichwörter der Autor:innen

AbobotulinumtoxinA (aboBoNT-A)Adult populationAnálisis de coste-efectividadCost-effectiveness analysisEspasticidad post-ictusPost-stroke spasticityRevisión sistemática de la literaturaSystematic literature reviewabobotulinumtoxinA (aboBoNT-A)población adulta

Substanzen

abobotulinumtoxinABotulinum Toxins, Type A

Autor:innen und Institutionen

  • Director of the Spanish Association for the Evaluation of Health Technologies, Pamplona, Navarra, Spain. Electronic address: maria.errea@aeets.es.
  • Ipsen, Madrid, Spain.
  • Fundación Gaspar Casal, Madrid, Spain.
  • Fundación Gaspar Casal, Madrid, Spain; Deusto Business School, Bilbao, Spain.

Zitieren

APA

Errea Rodríguez, M., Fernández, M., Del Llano, J., & Nuño-Solinís, R. (2023). Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2023.04.006

Vancouver

Errea Rodríguez M, Fernández M, Del Llano J, Nuño-Solinís R. Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy. Farmacia Hospitalaria. 2023. doi:10.1016/j.farma.2023.04.006

BibTeX
@article{ErreaRodrguez2023,
  author = {Errea Rodríguez, María and Fernández, María and Del Llano, Juan and Nuño-Solinís, Roberto},
  title = {Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy},
  journal = {Farmacia Hospitalaria},
  year = {2023},
  doi = {10.1016/j.farma.2023.04.006}
}
Kostenlos starten →